Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of venetoclax plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
MOH_2020-07-27_009172Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Venetoclax + azacitidine with Placebo + azacitidine (2 arms). Started Jun 2020; status: completed.
02
Drugs
venetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2020-07-27_009172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-27_009172.